Researcher | Research Overview
Dr. Pal's laboratory is focused on studying the mechanism of renal injury, renal inflammation and renal cancer, with particular importance paid to the signal transduction pathways regulating gene expression. One of the main focuses of Dr. Pal's research is to identify molecular mechanisms of cancer growth in patients receiving organ transplants. For instance, it has been shown that although calcineurin inhibitors (CNI) are very good immunosuppressive agents, they can promote cancer, while the mTOR inhibitor rapamycin (RAPA) can inhibit cancer growth. Dr. Pal's work has demonstrated that treatment with CNI can activate the Ras-Raf-Nrf2-HO-1 signaling cascade, which plays a critical role in renal cancer growth. Dr. Pal has developed a sophisticated murine model to study the mechanism of post-transplantation cancer growth. Dr. Pal's research aims to identify molecular targets to develop novel drugs for the treatments of renal inflammation and cancer.
Researcher | Research Background
Dr. Pal received his Ph.D. in Physiology from University of Calcutta. He did his post-doctoral research in the field of angiogenesis at Beth Israel Deaconess Medical Center and Harvard Medical School.